An anonymous director reports

VENTRIPOINT DIAGNOSTICS MAKES SIGNIFICANT SALE TO THE LARGEST HEART CENTER IN GERMANY

A Ventripoint Diagnostics Ltd. VMS+ product has been purchased by and is fully operational in the Deutsches Herzzentrum der Charite (DHZC), German Heart Center, in Berlin, Germany.

Prof. Felix Berger, director of the clinic for congenital heart disease -- pediatric cardiology at DHZC, stated: "VMS+ not only gives us a very precise spatial view of complex congenital malformations at any time, but it also provides us with important data on the function of the heart muscle. This allows us to plan therapy even more precisely, check it at any time and adjust it if necessary."

The DHZC is the university heart centre of Charite-Universitatsmedizin Berlin, which is the largest heart centre in Germany for the treatment of all cardiovascular diseases in patients of all ages. The Charite is one of Germany's most research-intensive medical institutions and was ranked this year as the seventh-best hospital in the world and the best in Europe by Newsweek. The DHZC's departments for congenital heart disease -- pediatric cardiology and congenital and pediatric heart surgery are among the leading institutions in Europe for the diagnosis and therapy of congenital and acquired heart disease (CHD). In 2021, the unit treated 1,005 statutory and 2,300 ambulatory CHD children. These numbers are continuously growing, with the patients coming from Eastern Europe and neighbouring countries. Approximately 6,000 children are born in Germany every year with heart defects that require treatment and lifelong monitoring. The German heart centre is the central point of contact for advice, diagnostics and therapy for the life of patients with CHD.

The VMS+ will be an asset to the hospital's pediatric cardiology led by Prof. Berger, a world-renowned pediatric cardiologist. The innovative product was purchased in order to improve efficacy and patient management in the CHD department. The VMS+ offers an accessible and timely cardiac diagnostic alternative to cMRI (cardiac magnetic resonance imaging). The VMS+ with Knowledge-Based Reconstruction (KBR) produces metrics that are more accurate and reliable compared with other standard ultrasound measurement techniques. This exciting new site will give the VMS+ larger visibility in the European market. Ventripoint strives to advance care for cardiovascular diseases for everyone and especially for children.

The DHZC's purchase was enabled by Ventripoint's partner in Europe, Angiopro GmbH, a leading German-based distributor.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.